col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

42 Results       Page 1

Wiley: British Journal of Pharmacology
  original article Date Title Authors   All Authors
1 [GO] 2022―Mar―29 Niclosamide - a promising treatment for COVID-19 Shivani Singh, Anne Weiss, James Goodman, Marie Fisk, Spoorthy Kulkarni, Ing Lu, et al. (+4)
2 [GO] 2022―Feb―19 Hypothesis: How far are we from predicting multi-drug interactions during treatment for COVID-19 infection? Benjamin Lozano, Javier Santibañez, Nicolás Severino, Cristina Saldias, Magdalena Vera, Jaime Retamal, et al. (+2)
3 [GO] 2021―Oct―11 Pyroptosis targeting via mitochondria: An educated guess to innovate COVID-19 therapies Aarti Singh, Daniela Strobbe, Michelangelo Campanella
4 [GO] 2021―Jul―31 Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine Loris Zamai, Marco B. L. Rocchi
5 [GO] 2021―Jul―08 Advocacy of targeting protease-activated receptors in severe coronavirus disease 2019 Saravanan Subramaniam, Wolfram Ruf, Markus Bosmann
6 [GO] 2021―Jun―15 Thromboinflammation in COVID-19: The Clot Thickens Raayma Iffah, Felicity N. E. Gavins
7 [GO] 2021―Jun―04 The Impact of COVID-19 on Pregnancy and Therapeutic Drug Development Allyah Abbas-Hanif, Homira Rezai, S. Faraz Ahmed, Asif Ahmed
8 [GO] 2021―Jun―01 Therapeutic potential of mega-dose vitamin C to reverse organ dysfunction in sepsis and COVID-19 Clive N. May, Rinaldo Bellomo, Yugeesh R. Lankadeva
9 [GO] 2021―May―08 Therapeutic strategies to fight COVID-19: Which is the status artis ? Cristina Scavone, Annamaria Mascolo, Concetta Rafaniello, Liberata Sportiello, Ugo Trama, Alice Zoccoli, et al. (+7)
10 [GO] 2021―Apr―07 Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro Sebastian Schloer, Linda Brunotte, Angeles Mecate-Zambrano, Shuyu Zheng, Jing Tang, Stephan Ludwig, Ursula Rescher
11 [GO] 2021―Mar―26 Dual inhibition of CB 1 R and iNOS as a potential novel approach to the pharmacological management of acute and long COVID-19 Resat Cinar, Malliga R. Iyer, George Kunos
13 [GO] 2021―Jan―06 COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31 Francesca Levi-Schaffer, Ario Marco
14 [GO] 2020―Dec―12 Can the hyperthermia-mediated Heat Shock Factor (HSF) /Heat Shock Protein (HSP) 70 pathway dampen the cytokine storm during SARS-CoV-2 infection? Cédric Rébé, François Ghiringhelli, Carmen Garrido
15 [GO] 2020―Dec―07 Low bioavailability hinders drug discovery against COVID-19, guided by in silico docking Priyankar Dey
16 [GO] 2020―Nov―03 Update on animal models for COVID-19 research Simon J. Cleary, Mélia Magnen, Mark R. Looney, Clive P. Page
17 [GO] 2020―Oct―30 Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations Julia A. Tree, Jeremy E. Turnbull, Karen R. Buttigieg, Michael J. Elmore, Naomi Coombes, John Hogwood, et al. (+14)
18 [GO] 2020―Sep―02 Databases for the Targeted COVID-19 Therapeutics Yunxia Wang, Fengcheng Li, Ying Zhang, Ying Zhou, Ying Tan, Yuzong Chen, Feng Zhu
19 [GO] 2020―Aug―12 Anti-inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H 2 S-donors in COVID-19 therapy Valentina Citi, Alma Martelli, Vincenzo Brancaleone, Simone Brogi, Gabriel Gojon, Rosangela Montanaro, et al. (+3)
20 [GO] 2020―Aug―10 The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: lessons for drug repurposing Ilaria Bertocchi, Federica Foglietta, Debora Collotta, Carola Eva, Vincenzo Brancaleone, Christoph Thiemermann, Massimo Collino
21 [GO] 2020―Jul―23 Non-steroidal anti-inflammatory drugs, prostaglandins and COVID-19 Calum T. Robb, Marie Goepp, Adriano G. Rossi, Chengcan Yao
22 [GO] 2020―Jul―22 Sex-Related Differences in COVID-19 Lethality Claudia Penna, Valentina Mercurio, Carlo G. Tocchetti, Pasquale Pagliaro
23 [GO] 2020―Jul―18 Safety perspectives on presently considered drugs for the treatment of COVID-19 Sophie L. Penman, Robyn T. Kiy, Rebecca L. Jensen, Christopher Beoku-Betts, Ana Alfirevic, David Back, et al. (+7)
24 [GO] 2020―Jul―16 Targeting zinc metalloenzymes in COVID-19 Urszula Doboszewska, Piotr Wlaź, Gabriel Nowak, Katarzyna Młyniec
25 [GO] 2020―Jul―09 Tackling COVID-19 infection through complement-targeted immunotherapy Sonata Jodele, Jörg Köhl
26 [GO] 2020―Jul―08 Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19? Krishna Sriram, Paul A. Insel
27 [GO] 2020―Jun―30 The many mechanisms of action of Chloroquine: to use or not to use (in COVID-19) that is the question Giuseppe Cirino, Amrita Ahluwalia
28 [GO] 2020―Jun―20 Novel Approach for Low-Dose Pulmonary Delivery of Hydroxychloroquine in COVID-19 Safa C. Fassihi, Neel R. Nabar, Reza Fassihi
29 [GO] 2020―Jun―20 Statins: Could an old friend help the fight against COVID-19? Raul R. Rodrigues-Diez, Antonio Tejera-Muñoz, Laura Marquez-Exposito, Sandra Rayego-Mateos, Laura Santos Sanchez, Vanessa Marchant, et al. (+5)
30 [GO] 2020―Jun―18 Harnessing resolving-based therapeutics to treat pulmonary viral infections: What can the future offer to COVID-19? Lirlândia P. Sousa, Vanessa Pinho, Mauro M. Teixeira
31 [GO] 2020―Jun―10 The potential of cannabidiol in the COVID-19 pandemic: a hypothesis letter Giuseppe Esposito, Marcella Pesce, Luisa Seguella, Walter Sanseverino, Jie Lu, Chiara Corpetti, Giovanni Sarnelli
32 [GO] 2020―Jun―04 A lesson from a saboteur: high molecular weight kininogen (HMWK) impact in COVID-19 Chiara Colarusso, Michela Terlizzi, Aldo Pinto, Rosalinda Sorrentino
33 [GO] 2020―May―28 Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology Simon J. Cleary, Simon C. Pitchford, Richard T. Amison, Robert Carrington, C. Lorena Robaina Cabrera, Mélia Magnen, et al. (+3)
34 [GO] 2020―May―22 A rationale for targeting the P2X7 receptor in Coronavirus disease 19 (Covid-19) Francesco Di Virgilio, Yong Tang, Alba Clara Sarti, Marco Rossato
35 [GO] 2020―May―22 Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for ARDS? Nicola Curtin, Krisztián Bányai, James Thaventhiran, John Le Quesne, Zsuzsanna Helyes, Péter Bai
36 [GO] 2020―May―22 The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS). Faleh Tamimi, Mohammad Abusamak, Bindu Akkanti, Zheng Chen, Seung-Hee Yoo, Harry Karmouty-Quintana
37 [GO] 2020―May―19 Lung tissue distribution of drugs as a key factor for COVID-19 treatment Yan Wang, Lei Chen
38 [GO] 2020―May―05 Potential Therapeutic Targets and Promising Drugs for Combating SARS-CoV-2 Hong Zhou, Yan Fang, Tao Xu, Wei-Jian Ni, Ai-Zong Shen, Xiao-Ming Meng
39 [GO] 2020―May―02 A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development. IUPHAR Review 29 S.P.H. Alexander, J. Armstrong, A.P. Davenport, J. Davies, E. Faccenda, S.D. Harding, et al. (+5)
40 [GO] 2020―Apr―29 Inhaled Nitric Oxide and COVID-19 Louis J. Ignarro
41 [GO] 2020―Apr―25 A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance Krishna Sriram, Paul A. Insel
42 [GO] 2020―Apr―24 Current pharmacological treatments for COVID-19: what’s next? Cristina Scavone, Simona Brusco, Michele Bertini, Liberata Sportiello, Concetta Rafaniello, Alice Zoccoli, et al. (+4)

42 Results       Page 1


Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.010 sec